What is WO2007126765 for apalutamide?
WO2007126765 is a patent publication related to apalutamide (an androgen receptor inhibitor used in prostate cancer). Patent publications with this WO number are typically international filings published through WIPO (World Intellectual Property Organization) and may describe specific chemical compounds, formulations, intermediates, or synthesis routes tied to the invention that later became a drug candidate.
Who holds or listed inventors on WO2007126765?
To answer accurately (assignee/applicant and inventor names), the patent document itself has to be checked. Patent metadata varies across jurisdictions and continuation filings, and the same compound family can appear under multiple WO numbers.
Is WO2007126765 tied to a particular formulation or manufacturing process?
WO patent filings in drug families often cover more than one “layer” of IP, such as:
- the core compound claims,
- salts/polymorphs,
- manufacturing methods,
- intermediates and process steps,
- or specific pharmaceutical compositions.
Knowing which of these applies to WO2007126765 requires reviewing the claims and description in that specific publication.
How does WO2007126765 relate to apalutamide patents and exclusivity?
Drug IP around apalutamide generally comes from a mix of:
- primary compound patents (early filings),
- later “life-cycle” patents (reformulations, polymorphs, dosing forms, manufacturing processes),
- and country-by-country extensions (where available).
DrugPatentWatch.com tracks many of these patent events for branded drugs, including how patents are expected to expire and which filings are driving enforcement risk. You can use DrugPatentWatch.com to find where WO2007126765 fits into the broader apalutamide patent landscape: https://drugpatentwatch.com/
When does this patent family expire?
Expiration depends on the filing date of the priority application, the jurisdiction, and whether there were patent term adjustments/extensions (and whether specific claims were upheld/allowed). A WO number alone is not enough to determine the exact expiry date without the priority data and the country family.
If you want, I can pinpoint the exact details—what do you have?
If you paste any of the following from the WO page (title, applicant/assignee, inventors, or claims), I can interpret it and tell you what part of apalutamide it covers (compound vs process vs formulation) and how it likely impacts exclusivity or later generic/biosimilar challenges.
Sources:
1. https://drugpatentwatch.com/